001067.KS
JW Pharmaceutical Corporation
KSEKRWEQUITY
Healthcare
DELAYED
Last price
46,800.00
▲ 1,800.00 (4.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
45,000.00
Prev close
45,000.00
Day high
46,800.00
Day low
45,000.00
Volume
26
Market cap
$1.08T
P/E (TTM)
—
52W range
38,500.00 – 63,300.00
Day trading desk
Gap from prior close
0.00%
Prior close 45,000.00
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
4.00%
45,000.00 – 46,800.00
Position in range
100%
Near session high
ATR (14D)
839.29
1.79% of price
Prior day high
45,000.00
PDH
Prior day low
44,050.00
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 75
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+5.14%
+6.3%
1M
+8.30%
+5.0%
3M
-12.79%
-15.2%
6M
-23.60%
-35.5%
YTD
-25.86%
-37.8%
1Y
-28.00%
-48.1%
3Y
-26.68%
-101.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on 001067.KS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
868.17K
Total on file
Fundamentals
Market cap$1.08T
Enterprise value$1.06T
Revenue (TTM)$820.86B
Gross profit$388.22B
EBITDA$127.31B
Net income$100.42B
EPS (TTM)—
Free cash flow$66.53B
Total cash$102.08B
Total debt$71.75B
Book value / share—
Shares outstanding206.75K
Float13.62M
Short % of float—
Dividend yield1.44%
Beta (5Y)0.99
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue1.29
EV / EBITDA8.31
Gross margin47.29%
Operating margin15.02%
Profit margin12.34%
Return on equity27.63%
Return on assets10.78%
Debt / equity17.50
Current ratio1.56
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $775.30B | $719.38B | $748.53B | $684.35B | +7.8% |
| Operating revenue | $775.30B | $719.38B | $748.53B | $684.35B | +7.8% |
| Cost of revenue | $415.98B | $395.88B | $412.98B | $396.40B | +5.1% |
| Gross profit | $359.31B | $323.50B | $335.54B | $287.95B | +11.1% |
| Research & development | $45.45B | $36.24B | $33.67B | $33.74B | +25.4% |
| Selling, general & admin | $167.11B | $157.92B | $152.64B | $126.74B | +5.8% |
| Total operating expense | $264.85B | $240.77B | $234.63B | $225.18B | +10.0% |
| Operating income | $94.46B | $82.73B | $100.92B | $62.78B | +14.2% |
| Net interest income | -$773.61M | -$4.92B | -$5.27B | -$2.74B | +84.3% |
| Pre-tax income | $88.84B | $82.42B | $54.84B | $45.36B | +7.8% |
| Tax provision | $27.32B | $17.38B | $16.41B | $15.51B | +57.2% |
| Net income | $61.51B | $65.04B | $37.01B | $31.89B | -5.4% |
| Net income to common | $61.51B | $65.04B | $37.01B | $31.89B | -5.4% |
| Basic EPS | 2,534.00 | 2,644.00 | 1,474.00 | 1,242.15 | -4.2% |
| Diluted EPS | 2,534.00 | 2,644.00 | 1,474.00 | 1,242.15 | -4.2% |
| EBIT | $93.26B | $92.45B | $67.40B | $54.75B | +0.9% |
| EBITDA | $112.01B | $111.55B | $89.97B | $71.59B | +0.4% |
| Basic shares | 24.27M | 24.60M | 25.11M | 25.67M | -1.3% |
| Diluted shares | 24.27M | 24.60M | 25.11M | 25.67M | -1.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $39.23B | $10.43B | $15.91B | $33.90B | — | +276.2% |
| Cash & short-term investments | $61.34B | $32.55B | $94.20B | $149.68B | — | +88.4% |
| Accounts receivable | $114.57B | $135.50B | $159.38B | $147.52B | — | -15.4% |
| Inventory | $109.90B | $111.73B | $106.09B | $111.67B | — | -1.6% |
| Total current assets | $296.51B | $306.41B | $378.09B | $425.46B | — | -3.2% |
| Property, plant & equipment | $165.28B | $172.29B | $155.72B | $123.05B | — | -4.1% |
| Goodwill & intangibles | $64.46B | $40.84B | $30.36B | $16.27B | — | +57.8% |
| Total assets | $605.27B | $604.60B | $645.04B | $627.97B | — | +0.1% |
| Total current liabilities | $209.16B | $208.62B | $286.93B | $380.13B | — | +0.3% |
| Current debt | $32.10B | $41.40B | $113.13B | $206.44B | — | -22.5% |
| Long-term debt | — | $25.10B | $30.00B | — | $120.74B | — |
| Total debt | $54.63B | $91.73B | $170.28B | $209.54B | — | -40.4% |
| Total liabilities | $235.90B | $275.11B | $379.60B | $402.21B | — | -14.3% |
| Retained earnings | $214.57B | $164.12B | $113.03B | $89.13B | — | +30.7% |
| Shareholder equity | $369.37B | $329.49B | $265.44B | $240.35B | — | +12.1% |
| Working capital | $87.35B | $97.80B | $91.16B | $45.33B | — | -10.7% |
| Net tangible assets | $304.91B | $288.65B | $235.08B | $224.09B | — | +5.6% |
| Shares issued | 22.55M | 23.27M | 22.84M | 23.30M | — | -3.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $61.51B | $65.04B | $38.43B | $29.85B | -5.4% |
| Depreciation & amortisation | $18.75B | $19.10B | $22.57B | $16.84B | -1.9% |
| Change in working capital | $8.42B | -$9.28B | -$20.26B | -$6.17B | +190.7% |
| Operating cash flow | $96.40B | $79.39B | $87.16B | $56.76B | +21.4% |
| Capital expenditure | -$36.12B | -$28.14B | -$40.71B | -$12.35B | -28.4% |
| Investing cash flow | -$7.20B | $14.08B | -$63.78B | -$18.92B | -151.1% |
| Share buybacks | -$9.54B | -$750.42M | -$260.88M | -$281.60M | -1,171.3% |
| Dividends paid | -$11.07B | -$9.67B | -$8.81B | -$7.35B | -14.5% |
| Financing cash flow | -$59.78B | -$100.19B | -$41.25B | -$36.91B | +40.3% |
| Free cash flow | $60.28B | $51.25B | $46.45B | $44.41B | +17.6% |
| End cash position | $39.23B | $10.43B | $15.91B | $33.90B | +276.2% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $199.88B | $198.94B | $200.02B | $191.10B | $185.24B | +0.5% |
| Operating revenue | $199.88B | $198.94B | $200.02B | $191.10B | $185.24B | +0.5% |
| Cost of revenue | $101.43B | $109.09B | $105.39B | $100.45B | $101.06B | -7.0% |
| Gross profit | $98.46B | $89.85B | $94.63B | $90.66B | $84.18B | +9.6% |
| Research & development | $9.38B | $15.27B | $7.33B | $12.76B | $10.09B | -38.5% |
| Selling, general & admin | $42.96B | $45.82B | $42.91B | $39.94B | $38.44B | -6.2% |
| Total operating expense | $64.88B | $74.39B | $62.60B | $65.69B | $62.17B | -12.8% |
| Operating income | $33.58B | $15.46B | $32.03B | $24.97B | $22.01B | +117.2% |
| Net interest income | $433.95M | $432.78M | -$339.22M | -$27.97M | -$839.20M | +0.3% |
| Pre-tax income | $35.20B | $17.49B | $27.85B | $20.63B | $22.86B | +101.2% |
| Tax provision | $7.72B | $2.18B | -$2.74B | $22.50B | $5.39B | +254.8% |
| Net income | $27.48B | $15.32B | $30.59B | -$1.87B | $17.47B | +79.4% |
| Net income to common | $27.48B | $15.32B | $30.59B | -$1.87B | $17.47B | +79.4% |
| Basic EPS | 1,138.00 | — | 1,267.00 | -77.00 | 714.00 | — |
| Diluted EPS | 1,138.00 | — | 1,267.00 | -77.00 | 714.00 | — |
| EBIT | $33.58B | $14.26B | $32.03B | $90.66B | $22.01B | +135.5% |
| EBITDA | $38.56B | $19.04B | $36.72B | $29.60B | $26.65B | +102.6% |
| Basic shares | 22.55M | — | 22.55M | 22.68M | 24.47M | — |
| Diluted shares | 22.55M | — | 22.55M | 22.68M | 24.47M | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $20.55B | $39.23B | $32.56B | $11.06B | $31.82B | — | -47.6% |
| Cash & short-term investments | $66.32B | $61.34B | $82.51B | $72.53B | $54.42B | — | +8.1% |
| Accounts receivable | $115.16B | $114.57B | $124.35B | $125.29B | $126.34B | — | +0.5% |
| Inventory | $114.74B | $109.90B | $116.30B | $119.46B | $121.58B | — | +4.4% |
| Total current assets | $308.90B | $296.51B | $331.96B | $324.82B | $323.52B | — | +4.2% |
| Property, plant & equipment | $162.41B | $165.28B | $164.40B | $166.32B | $169.32B | — | -1.7% |
| Goodwill & intangibles | $66.59B | $64.46B | $55.38B | $47.16B | $44.27B | — | +3.3% |
| Total assets | $621.61B | $605.27B | $611.56B | $590.08B | $611.04B | — | +2.7% |
| Total current liabilities | $211.35B | $209.16B | $220.10B | $230.45B | $219.18B | — | +1.0% |
| Current debt | $32.10B | $32.10B | $45.10B | $66.40B | $30.00B | — | 0.0% |
| Long-term debt | — | — | — | — | $25.10B | $25.10B | — |
| Total debt | $54.12B | $54.63B | $68.66B | $90.73B | $79.69B | — | -0.9% |
| Total liabilities | $239.83B | $235.90B | $257.46B | $266.80B | $279.96B | — | +1.7% |
| Retained earnings | $226.34B | $214.57B | $199.25B | $168.66B | $170.53B | — | +5.5% |
| Shareholder equity | $381.78B | $369.37B | $354.10B | $323.28B | $331.09B | — | +3.4% |
| Working capital | $97.54B | $87.35B | $111.85B | $94.37B | $104.34B | — | +11.7% |
| Net tangible assets | $315.19B | $304.91B | $298.72B | $276.12B | $286.82B | — | +3.4% |
| Shares issued | 23.29M | 22.55M | 23.29M | 23.29M | 23.28M | — | +3.3% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $27.48B | $15.32B | $30.59B | -$1.87B | $17.47B | — | +79.4% |
| Depreciation & amortisation | $4.99B | $4.78B | $4.69B | $4.63B | $4.64B | — | +4.3% |
| Change in working capital | -$21.55B | $4.15B | $13.41B | -$12.02B | $2.87B | — | -618.8% |
| Operating cash flow | $17.50B | $27.55B | $46.92B | -$6.65B | $28.58B | — | -36.5% |
| Capital expenditure | -$6.57B | -$13.49B | -$9.80B | -$4.58B | -$8.26B | — | +51.3% |
| Investing cash flow | -$35.39B | -$6.62B | -$3.00B | -$7.66B | $10.09B | — | -434.6% |
| Share buybacks | — | $10 | $0 | -$4.79B | -$4.75B | -$417.97M | — |
| Dividends paid | — | $0 | $0 | — | — | $0 | — |
| Financing cash flow | -$1.13B | -$14.18B | -$22.49B | -$5.76B | -$17.34B | — | +92.0% |
| Free cash flow | $10.93B | $14.06B | $37.12B | -$11.23B | $20.32B | — | -22.3% |
| End cash position | $20.55B | $39.23B | $32.56B | $11.06B | $31.82B | — | -47.6% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders3.59%
Held by institutions0.00%
Institutions holding0
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
44,250.00
+5.76% from price
SMA 20
43,922.50
+2.45% from price
SMA 50
43,423.00
+3.63% from price
SMA 100
48,308.00
-3.12% from price
SMA 200
53,862.00
-16.45% from price
EMA 12
44,283.01
+5.68% from price
EMA 26
43,985.62
+6.40% from price
EMA 50
44,792.19
+4.48% from price
RSI (14)
57.6
Neutral
MACD (12,26,9)
297.39
Hist 211.40
ATR (14)
839.29
1.87% of price
Realised vol 30D
28.3%
Annualised
Bollinger upper
45,190.36
20, 2σ
Bollinger lower
42,654.64
20, 2σ
50 / 200 cross
Death
43,423.00 vs 53,862.00
Trend bias
Below 200
-16.45%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-0.13
Less volatile than market
Correlation to SPY
-0.07
Largely independent
Realised vol 30D
28.3%
Annualised
Market vol 1Y
12.8%
SPY, annualised
Max drawdown 1Y
-35.2%
Peak to trough
Max drawdown 5Y
-43.2%
Peak to trough
ATR 14
839.29
1.87% of price
Beta (reported)
0.99
5Y monthly, from filing
Dividends & splits
Forward rate$650.00 / yr
Forward yield1.44%
5-year avg yield0.61%
Payout ratio15.53%
Ex-dividend dateMar 31, 2026
Next pay date—
Last split1.02:1
Split dateDec 27, 2023
Headlines
REVOLVE Unveils the Porsche Collection by REVOLVE
PR Newswire · 4m ago
Luxor Energy and Bentaus Complete First AI GPU Response to ERCOT 4CP Signals
PR Newswire · 4m ago
Oppenheimer Hires Bruce Rideaux and Promotes Lauren Carter As Public Finance Business Continues to Expand
PR Newswire · 4m ago
Why Kevin Warsh's Jackson Hole speech may not be a big inflection point for Fed
Yahoo Finance Video · 4m ago
Outmarket AI Joins New Applied Systems Vendor Certification Program
PR Newswire · 4m ago
BRC Therapeutics Appoints Biopharma Veteran Chandra Ramanathan as Executive Vice President of Commercialization and Strategy
PR Newswire · 4m ago
DQS Inc. Achieves ANAB Accreditation for ISO 14001:2026
PR Newswire · 4m ago
Graebel Launches Switch, an AI-Powered Virtual Relocation Assistant, for Graebel CitySwitcher®
PR Newswire · 4m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.